Findings

What do systematic reviews say?

11 questions · 12 findings · 2 reviews · Vascular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 16.7%GRADE not reported 3 · 25%Very low 0 · 0%Low 2 · 16.7%Moderate 5 · 41.7%High 0 · 0%

Low molecular weight heparin vs UFH

Incidence of recurrent VTE1 after initial treatment (up to 15 days) · patients with venous thromboembolism.

LMWH probably leads to lower incidence of recurrent VTE1 after initial treatment (up to 15 days) compared with UFH (moderate certainty).

1 finding from 1 review

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial… 2017 · Cochrane Headline outcomes only
OR 0.69 [0.49, 0.98]
18 studies · 6238 participants
Moderate

Low molecular weight heparin vs UFH

Recurrent VTE · patients with venous thromboembolism.

LMWH probably leads to lower incidence of recurrent VTE1 (3 months compared with UFH (moderate certainty).

2 findings from 1 review

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial… 2017 · Cochrane Headline outcomes only
OR 0.71 [0.56, 0.9]
16 studies · 6661 participants
Moderate
Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial… 2017 · Cochrane Headline outcomes only
OR 0.72 [0.59, 0.88]
22 studies · 9489 participants
Moderate

Low molecular weight heparin vs UFH

Reduction in thrombus size (pre‐ and post‐treatment venograms) · patients with venous thromboembolism.

LMWH may leads to lower reduction in thrombus size (pre‐ and post‐treatment venograms) compared with UFH (low certainty).

1 finding from 1 review

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial… 2017 · Cochrane Headline outcomes only
OR 0.71 [0.61, 0.82]
16 studies · 2909 participants
Low

Low molecular weight heparin vs UFH

Major bleeding · patients with venous thromboembolism.

LMWH probably leads to lower incidence of major haemorrhagic episodes (during initial treatment ‐… compared with UFH (moderate certainty).

1 finding from 1 review

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial… 2017 · Cochrane Headline outcomes only
OR 0.69 [0.5, 0.95]
25 studies · 8780 participants
Moderate

Low molecular weight heparin vs UFH

Overall mortality (end of · patients with venous thromboembolism.

LMWH showed no clear difference in overall mortality (end of compared with UFH (moderate certainty).

1 finding from 1 review

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial… 2017 · Cochrane Headline outcomes only
OR 0.84 [0.7, 1.01]
24 studies · 9663 participants
Moderate

ASA + high‐dose LMWH vs ASA + low‐dose LMWH or UFH

Thrombosis · people with antiphospholipid antibodies and no history of thrombosis

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 120 participants
GRADE not reported

ASA + high‐dose LMWH vs ASA + low‐dose LMWH or UFH

Bleeding ‐ major/excessive · people with antiphospholipid antibodies and no history of thrombosis

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 120 participants
GRADE not reported

ASA + high‐dose LMWH vs ASA + low‐dose LMWH or UFH

Subcutaneous bruises · people with antiphospholipid antibodies and no history of thrombosis

ASA + high‐dose LMWH showed no clear difference in subcutaneous bruises compared with ASA + low‐dose LMWH or UFH (low certainty).

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
RR 1 [0.34, 2.93]
2 studies · 120 participants
Low

ASA + high‐dose LMWH vs ASA + low‐dose LMWH or UFH

All‐cause mortality · people with antiphospholipid antibodies and no history of thrombosis

The review found no eligible studies for this question.

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

ASA + high‐dose LMWH vs ASA + low‐dose LMWH or UFH

Quality of life · people with antiphospholipid antibodies and no history of thrombosis

The review found no eligible studies for this question.

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

ASA + high‐dose LMWH vs ASA + low‐dose LMWH or UFH

Adverse events other than bleeding · people with antiphospholipid antibodies and no history of thrombosis

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported